Michel Andréjak

2.4k total citations
115 papers, 1.6k citations indexed

About

Michel Andréjak is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Pharmacology. According to data from OpenAlex, Michel Andréjak has authored 115 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Surgery, 28 papers in Cardiology and Cardiovascular Medicine and 23 papers in Pharmacology. Recurrent topics in Michel Andréjak's work include Pharmacological Effects and Toxicity Studies (12 papers), Antibiotics Pharmacokinetics and Efficacy (10 papers) and Pharmacology and Obesity Treatment (9 papers). Michel Andréjak is often cited by papers focused on Pharmacological Effects and Toxicity Studies (12 papers), Antibiotics Pharmacokinetics and Efficacy (10 papers) and Pharmacology and Obesity Treatment (9 papers). Michel Andréjak collaborates with scholars based in France, United States and Switzerland. Michel Andréjak's co-authors include L Hary, Henri Masson, Christophe Tribouilloy, Ziad A. Massy, Kamel Masmoudi, Valérie Gras‐Champel, Valérie Gras, Marcel Peltier, Michel Slama and Gabriel Choukroun and has published in prestigious journals such as Circulation, CHEST Journal and European Heart Journal.

In The Last Decade

Michel Andréjak

111 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michel Andréjak France 22 426 396 219 210 202 115 1.6k
John A. Opsahl United States 17 457 1.1× 197 0.5× 189 0.9× 200 1.0× 206 1.0× 48 1.1k
Diane K. Jorkasky United States 27 425 1.0× 353 0.9× 144 0.7× 341 1.6× 180 0.9× 68 1.7k
Rocco C. Venuto United States 25 328 0.8× 292 0.7× 209 1.0× 168 0.8× 246 1.2× 103 2.1k
Moshe Garty Israel 25 671 1.6× 362 0.9× 73 0.3× 160 0.8× 206 1.0× 88 1.8k
John D. Wallin United States 24 452 1.1× 287 0.7× 108 0.5× 210 1.0× 117 0.6× 67 1.7k
Atef Halabi Germany 25 805 1.9× 306 0.8× 242 1.1× 505 2.4× 315 1.6× 79 2.2k
N Pozet France 20 275 0.6× 176 0.4× 163 0.7× 131 0.6× 199 1.0× 86 1.1k
K L Woods United Kingdom 18 957 2.2× 228 0.6× 138 0.6× 245 1.2× 213 1.1× 54 2.0k
Donald R.J. Singer United Kingdom 27 1.2k 2.8× 300 0.8× 102 0.5× 246 1.2× 308 1.5× 102 2.3k
Consuelo Huerta Spain 22 361 0.8× 553 1.4× 423 1.9× 188 0.9× 201 1.0× 66 2.3k

Countries citing papers authored by Michel Andréjak

Since Specialization
Citations

This map shows the geographic impact of Michel Andréjak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Andréjak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Andréjak more than expected).

Fields of papers citing papers by Michel Andréjak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Andréjak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Andréjak. The network helps show where Michel Andréjak may publish in the future.

Co-authorship network of co-authors of Michel Andréjak

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Andréjak. A scholar is included among the top collaborators of Michel Andréjak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Andréjak. Michel Andréjak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ennezat, Pierre‐Vladimir, et al.. (2017). From evidence-based medicine to personalized medicine, with particular emphasis on drug-safety monitoring. Archives of cardiovascular diseases. 110(6-7). 413–419. 7 indexed citations
2.
3.
Andréjak, Michel & Christophe Tribouilloy. (2013). Drug-induced valvular heart disease: An update. Archives of cardiovascular diseases. 106(5). 333–339. 30 indexed citations
4.
Bodeau, Sandra, Anne‐Sophie Lemaire‐Hurtel, Catherine François, et al.. (2013). The End-of-Treatment Ribavirin Concentration Predicts Hepatitis C Virus Relapse. Therapeutic Drug Monitoring. 35(6). 791–795. 6 indexed citations
5.
Tribouilloy, Christophe, Sylvestre Maréchaux, Antoine Jeu, et al.. (2013). Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study. European Heart Journal. 34(46). 3580–3587. 10 indexed citations
6.
Tribouilloy, Christophe, et al.. (2010). Restrictive organic mitral regurgitation associated with benfluorex therapy. European Journal of Echocardiography. 11(7). 614–621. 21 indexed citations
7.
Temmar, M., Sophie Liabeuf, C. Renard, et al.. (2009). Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. Journal of Hypertension. 28(1). 163–169. 147 indexed citations
8.
Gras‐Champel, Valérie, et al.. (2007). Angio-œdèmes iatrogènes: rôle des inhibiteurs de l'enzyme de conversion et des antagonistes des récepteurs à l'angiotensine II (sartans). Néphrologie & Thérapeutique. 3(3). 89–95. 7 indexed citations
9.
Gras, Valérie, G. Chaby, V. Strunski, et al.. (2004). Angio-œdèmes et inhibiteurs de l'enzyme de conversion de l'angiotensine : à propos de 19 cas. La Revue de Médecine Interne. 25(7). 501–506. 12 indexed citations
10.
Massy, Ziad A. & Michel Andréjak. (2004). Intérêt des statines en néphrologie. La Presse Médicale. 33(17). 1207–1212. 1 indexed citations
11.
Vittecoq, Daniel, L. Escaut, Gilles Chironi, et al.. (2003). Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS. 17. S70–S76. 72 indexed citations
12.
Hary, L, et al.. (2000). Etude pharmaco-clinique comparative de la ceftriaxone par voie sous-cutanée et intraveineuse chez la personne âgée. 25(5). 337–347. 13 indexed citations
13.
Andréjak, Michel, et al.. (1992). [Rhabdomyolysis associated to fenoverin therapy and complicated by acute renal failure].. PubMed. 47(2). 165–6. 2 indexed citations
14.
Andréjak, Michel, et al.. (1992). [Neurologic side effects of fluoroquinolones. Apropos of 9 cases concerning pefloxacin].. PubMed. 47(5). 415–8. 6 indexed citations
15.
Andréjak, Michel, et al.. (1991). A double‐blind comparison of perindopril and hydrochlorothiazide‐amiloride in mild to moderate essential hypertension. Fundamental and Clinical Pharmacology. 5(3). 185–192. 10 indexed citations
16.
Andréjak, Michel, et al.. (1991). The Clinical Significance of Antibiotic-Associated Pseudomembranous Colitis in the 1990s. Drug Safety. 6(5). 339–349. 12 indexed citations
17.
Hary, L, Michel Andréjak, Stéphane Leleu, J Orfila, & Jean‐Pierre Capron. (1989). The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites. European Journal of Clinical Pharmacology. 36(6). 613–616. 37 indexed citations
18.
Andréjak, Michel, et al.. (1987). Diltiazem Increases Steady State Digoxin Serum Levels in Patients with Cardiac Disease. The Journal of Clinical Pharmacology. 27(12). 967–970. 17 indexed citations
19.
Coevoet, B, Claude Desplan, J. L. Sébert, et al.. (1980). Effect of propranolol and metoprolol on parathyroid hormone and calcitonin secretions in uraemic patients.. BMJ. 280(6228). 1344–1346. 8 indexed citations
20.
Andréjak, Michel, et al.. (1978). [Beta-blockaders in the treatment of arterial hypertension. Part I. Pharmacologic, hemodynamic and metabolic aspects].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 17(1). 113–22. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John A. Opsahl Breakdown of academic impact, for papers by Diane K. Jorkasky Breakdown of academic impact, for papers by Rocco C. Venuto Breakdown of academic impact, for papers by Moshe Garty Breakdown of academic impact, for papers by John D. Wallin Breakdown of academic impact, for papers by Atef Halabi Breakdown of academic impact, for papers by N Pozet Breakdown of academic impact, for papers by K L Woods Breakdown of academic impact, for papers by Donald R.J. Singer Breakdown of academic impact, for papers by Consuelo Huerta
Rankless by CCL
2026